spdb

SPDB is a degradable ADC linker that can be used to synthesize antibody-drug conjugates. SPDB is a small fragment attached to the DM4 conjugate and conjugated to the antibody using a disulfide bond.

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

SPDB-sulfo, a glutathione-cleavable linker, is utilized in the development of antibody-drug conjugates (ADCs) [1].

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

sulfo-SPDB is a cleavable linker vital in ADC synthesis. sulfo-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

Lys-Nε-SPDB-DM4 is a drug-linker conjugate that integrates the tubulin inhibitor DM4 with the linker Lys-Nε-SPDB, enabling the formation of an antibody-drug conjugate (ADC).

NO2-SPDB-sulfo, a cleavable linker essential in ADC synthesis, connects cytotoxic drugs to antibodies, allowing targeted delivery to cells or proteins. Its cleavable nature ensures controlled drug release, optimizing the effectiveness of ADCs.

DMAC-SPDB is a cleavable linker vital in ADC synthesis. DMAC-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

DMAC-SPDB-sulfo is a cleavable linker essential in ADC synthesis, enabling precise delivery of cytotoxic drugs to cells or proteins by attaching them to antibodies. Its cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

SPDB-DM4 is a part of the ADC. It is composed of DM1 (a microtubule inhibitor, also an antibody-encodable aristolochic acid alkaloid, used to overcome the systemic toxicity associated with aristolochic acid and enhance tumor-specific delivery) and SPDB, and exhibits highly efficient anti-tumor activity.

Sulfo-SPDB-DGN462 is an agent-linker conjugate utilized for Antibody-Drug Conjugates (ADCs), featuring the potent DNA-alkylating agent DGN462 known for its anti-tumor properties, including efficacy against acute myeloid leukemia (AML), and is conjugated via the cleavable Sulfo-SPDB linker.

Dimethylamine-SPDB is a cleavable linker utilized in creating antibody-drug conjugates (ADCs) [1].